ClinicalTrials.gg
Not yet recruitingNCT07782788Updated Aug 24, 2026

Predictors of Cardiac Arrhythmia in Rheumatoid Arthritis Patients

An observational study in Rheumatoid Arthritis (RA), sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by Assiut University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
120
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Arthritis, Rheumatoid by Assiut University — 22 open to participants now, 22 under way, none of them phase 3. Arthritis, Rheumatoid · Assiut University.

Planned enrollment
6th of 43
120 · median 80
Started
2026
with 9 others
Observational
43 of 49
21 open now
Primary completion
2027-10
later than 15 of 21 live
Registered
44th of 49
by date

Among the 49 studies in Arthritis, Rheumatoid by Assiut University, this one is the 6th largest by planned enrollment of the 43 observational ones that give a count, is one of 10 that started in 2026, is one of 43 observational ones, reaches primary completion later than 15 of the 21 other live ones, and was the 44th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

22 of the 49 studies in Arthritis, Rheumatoid by Assiut University are open now, in 1 country. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 22 open studies →

Where they have run

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Arthritis, Rheumatoid by Assiut University, or all of them as a file.
02

Study summary

To evaluate QT dispersion, P-wave dispersion and Tp-e dispersion as predictors of cardiac arrhythmias in patients with rheumatoid arthritis and to assess their relationship with disease characteristics and inflammatory activity

Read the detailed description

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized primarily by persistent synovial inflammation and progressive joint destruction. In addition to musculoskeletal manifestations, patients with RA have an increased risk of cardiovascular morbidity and mortality compared with the general population. Cardiac arrhythmias represent one of the important cardiovascular complications in these patients and may contribute to sudden cardiac death Electrocardiographic markers reflecting abnormalities in atrial and ventricular depolarization and repolarization have gained increasing attention as predictors of arrhythmogenic risk. QT dispersion (QTd) reflects heterogeneity of ventricular repolarization and has been associated with ventricular arrhythmias. P-wave dispersion (PWD) represents inhomogeneous atrial conduction and is considered a predictor of atrial arrhythmias, particularly atrial fibrillation. Tp-e interval and Tp-e dispersion are relatively newer markers reflecting transmural dispersion of ventricular repolarization and have been linked to malignant ventricular arrhythmias Chronic inflammation, autonomic dysfunction, endothelial dysfunction and myocardial involvement in rheumatoid arthritis may contribute to abnormalities in these electrocardiographic parameters. Early identification of patients at higher risk of cardiac arrhythmias may improve risk stratification and allow timely intervention. Therefore, the present study aims to evaluate QT dispersion, P-wave dispersion and Tp-e dispersion as predictors of cardiac arrhythmias in patients with rheumatoid arthritis

03

Conditions studied

  • Rheumatoid Arthritis (RA)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

adult male and female participants aged ≥18 years, including patients with rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria and age- and sex matched healthy controls. Participants with other autoimmune diseases, thyroid disorders, cardiac diseases, electrolyte abnormalities (hypocalcemia, hypokalemia, or hypomagnesemia), or use of drugs known to affect cardiac rhythm such as amiodarone will be excluded

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria
  • Age ≥18 years
  • Male and female patients

Exclusion criteria

Exclusion Criteria:

  • Presence of other diseases
  • Thyroid disorders
  • Use of medications affecting cardiac conduction or repolarization such as amiodarone and other antiarrhythmic drugs
  • Electrolyte disturbances including hypocalcemia, hypokalemia and hypomagnesemia
  • Known cardiac diseases including ischemic heart disease, valvular heart disease, cardiomyopathy, heart failure or congenital heart disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No

Groups and cohorts

  • group 1 rheumatoid arthritis patients

    rheumatoid arthritis patients diagnosed according to 2010 ACR\\EULAR criteria

  • group 2 healthy controls

    healthy controls without RA meeting study eligibility criteria

06

What researchers measure

Primary outcomes

  1. QT dispersion, P-wave dispersion and Tp-e dispersion

    to assess QT dispersion , P wave dispersion and Tp-e dispersion on 12 lead ECG and compare their values between rheumatoid arthritis patients and healthy controls and to evaluate their association with the risk of cardiac arrhythmia

    Time frame: baseline

Secondary outcomes

  1. Correlation between ECG parameters and disease activity assessed by DAS28

    to evaluate the correlation between QT dispersion P wave dispersion Tp-e dispersion with rheumatoid arthritis disease activity assessed by DAS28

    Time frame: at baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Cindas A, Gokce-Kutsal Y, Tokgozoglu L, Karanfil A. QT dispersion and cardiac involvement in patients with rheumatoid arthritis. Scand J Rheumatol. 2002;31(1):22-6. doi: 10.1080/030097402317255327. PubMed 11922196 ↗
  • Gulkesen A, Yildirim Uslu E, Akgol G, Alkan G, Kobat MA, Gelen MA, Uslu MF. Is the development of arrhythmia predictable in rheumatoid arthritis? Arch Rheumatol. 2024 Aug 26;39(3):429-435. doi: 10.46497/ArchRheumatol.2024.10590. eCollection 2024 Sep. PubMed 39507840 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.

Of 235 non-industry observational studies under Arthritis, Rheumatoid, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 122. This study's planned 12 months is below that.

Counting every sponsor, half of 390 studies reached it within 50 months; a quarter within 25 and three quarters within 113.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2026
First posted
Aug 24, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Oct 1, 2027
CompletionEst.
Nov 1, 2027
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07782788
Lead sponsor
Assiut University
Responsible party
Katreen Nabeh Henin (Resident Physician, Assiut University) — Principal investigator
First posted
Aug 24, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Oct 1, 2027 (estimated)
Completion
Nov 1, 2027 (estimated)
Last update
Aug 24, 2026

Study contacts

katreen N henin, master
Contact
Katrin.18313203@med.aun.edu.eg
+2001553202412
katreen N henin, master
principal investigator · faculty of medicine , Assiut university ,Eygpt

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion